Concurrent expression of f-circM9 and MLL-AF9 protein contributed to leukemia progression in in vivo and ex vivo models, and f-circM9 expression increased drug resistance of leukemic cells (Guarnerio et al., 2016). The gene discussed is KMT2A; the disease is leukemia.